自身免疫性结旁病诊断方法的比较分析性能
该研究评估了五种自身免疫性结旁病(AN)诊断方法单独及联合使用的性能,样本为欧洲队列290例个体,采用贝叶斯潜类别分析估计灵敏度和特异度。结果显示,in-house CBA灵敏度最高(96%),所有方法特异度≥97%,联合两种方法(CBA和ImmunoDOT)可提高诊断准确性。
要点
- in-house CBA灵敏度最高(96%),所有方法特异度均≥97%。
- 联合两种方法(CBA和ImmunoDOT)可提高AN诊断准确性。
- 多数方法实验室间重复性良好(Gwet一致性系数>0.94)。
核心结论
- 联合CBA和ImmunoDOT两种方法可提高AN诊断准确性,有助于标准化诊断。
研究设计与样本
- 研究纳入欧洲队列290例个体,包括健康对照及吉兰-巴雷综合征、慢性炎性脱髓鞘性多发性神经根神经病、单克隆丙种球蛋白病、腓骨肌萎缩症和AN患者。
主要发现
- 总体灵敏度:ImmunoDOT 84%(95%CI 79-88),ELISA 86%(81-90),in-house CBA 96%(93-98),商业CBA 92%(89-96),IHC 91%(87-94)。
- 所有方法总体特异度均≥97%。
- in-house CBA表现最佳,灵敏度和特异度均最高。
- 方法联合分析性能优异:灵敏度≥91%,特异度≥98%。
- 实验室间验证显示良好的重复性,多数方法Gwet一致性系数>0.94。
关键数值与推荐
- in-house CBA灵敏度96%(95%CI 93-98),特异度≥97%。
- 商业CBA灵敏度92%(95%CI 89-96),特异度≥97%。
- IHC灵敏度91%(95%CI 87-94),特异度≥97%。
- ELISA灵敏度86%(95%CI 81-90),特异度≥97%。
- ImmunoDOT灵敏度84%(95%CI 79-88),特异度≥97%。
临床怎么用
- 推荐联合使用CBA和ImmunoDOT两种方法以提高AN诊断准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autoimmune nodopathy (AN) is a disabling peripheral nerve disorder mediated by four pathogenic autoantibodies targeting the node of Ranvier: anti-neurofascin-155 (Nfasc155); anti-Nfasc155 and Nfasc186 (PanNfasc); anti-contactin-1; and anti-contactin-associated protein 1 autoantibodies. Several autoantibody detection assays exist; however, which assay yields the best performance remains unclear. We evaluated the performance of five diagnostic assays individually and in combinations to identify a gold standard assay for diagnosing AN and improve diagnostic accuracy. METHODS: Sera from 290 individuals from a European cohort, including healthy controls and patients with Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, monoclonal gammopathy, Charcot-Marie-Tooth disease, and AN were tested using five diagnostic assays for AN: ImmunoDOT (D-tek, Mons, Belgium); ELISA; an in-house cell-based assay (CBA); a commercial CBA (Euroimmun, Bussy-Saint-Martin, France); and peripheral nerve immunohistochemistry (IHC). The sensitivity (Se) and specificity (Sp) of the individual assays and their combinations were estimated using Bayesian latent class analysis. RESULTS: The overall Se was 84% (95% credibility interval [CI], 79-88) for ImmunoDOT, 86% (81-90) for ELISA, 96% (93-98) for the in-house CBA, 92% (89-96) for the commercial CBA, and 91% (87-94) for IHC. For all assays, the overall Sp was ≥ 97%. Among the tested assays, in-house CBA showed the best performance, with the highest Se and Sp. The assay combinations demonstrated excellent analytical performance (Se ≥ 91% and Sp ≥ 98%). Inter-laboratory validation revealed excellent repeatability, with a Gwet's agreement coefficient of >0.94 for most assays. CONCLUSIONS: Our research suggests that combining two assays, CBA and ImmunoDOT enhances the accuracy of AN diagnosis. This approach can facilitate the establishment of standardized assays for AN diagnosis and aid in the better differentiation of AN from other similar pathologies.
引用
- Jentzer A, Serrand C, Vegezzi E, et al. Comparative Analytical Performance of Autoimmune Nodopathy Diagnostic Assays. Ann Lab Med. 2025. PMID: 41412761. doi:10.3343/alm.2025.0534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。